AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 2.24 |
Market Cap | 445.18M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.67 |
PE Ratio (ttm) | -3.37 |
Forward PE | n/a |
Analyst | Buy |
Ask | 2.31 |
Volume | 4,123,279 |
Avg. Volume (20D) | 5,889,881 |
Open | 2.30 |
Previous Close | 2.28 |
Day's Range | 2.23 - 2.40 |
52-Week Range | 1.58 - 3.94 |
Beta | undefined |
About ESPR
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration a...
Analyst Forecast
According to 5 analyst ratings, the average rating for ESPR stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 121.30% from the latest price.
Next Earnings Release
Analysts project revenue of $63.06M, reflecting a 95.53% YoY growth and earnings per share of -0.13, making a -74.00% decrease YoY.